Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.79 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.79 |
| ▸ | INSR | P06213 | 2/20 | 0.69 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.69 |
| ▸ | ROS1 | P08922 | 1/20 | 0.69 |
| ▸ | FER | P16591 | 1/20 | 0.69 |
| ▸ | LTK | P29376 | 1/20 | 0.69 |
| ▸ | BLK | P51451 | 1/20 | 0.69 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.69 |
| ▸ | BTK | Q06187 | 1/20 | 0.69 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.69 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.69 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.69 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16781018 | 0.96 | EGFR (0.75) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL19027405 | 0.91 | ALK (0.89) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL19027794 | 0.91 | ALK (0.95) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL19027947 | 0.90 | ALK (0.84) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL19027384 | 0.90 | ALK (0.82) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL19027381 | 0.90 | ALK (0.82) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL20537120 | 0.90 | ALK (0.83) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL19027412 | 0.89 | ALK (0.85) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL19027410 | 0.89 | ALK (0.82) | EGFRALKINSRERBB2ROS1 | |
| SCHEMBL23248556 | 0.89 | EGFR (0.71) | EGFRALKINSRIGF1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-10350210-B2 | EGFR and ALK dual inhibitor | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2019-07-16 | — | — | US | disclosed |
| US-20180369242-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | PRECEDO PHARMACEUTICALS CO., LTD (CN) | 2018-12-27 | — | — | US | disclosed |
| EP-3392245-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | Precedo Pharmaceuticals Co., Ltd. (CN) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017101803-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | 合肥中科普瑞昇生物医药科技有限公司 | 2017-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180369242-A1 | NOVEL EGFR AND ALK DUAL INHIBITOR | ALK, EGFR, NPM1 | EGFR 2/4885ALK 1/4885INSR 909/4885 |
| US-10350210-B2 | EGFR and ALK dual inhibitor | ALK, EGFR, ERBB2 | EGFR 2/4885ALK 1/4885INSR 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.